Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Bio-Path Holdings, Inc. BPTH OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
39/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Bio-Path Holdings, Inc. (BPTH) is a Biotechnology company in the Healthcare sector, currently trading at $0.06. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $10M (loss), growing at -3.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $83,000 against $154,000 equity (Debt-to-Equity (D/E) ratio 0.54, moderate). Current ratio is 1.15 (adequate). Debt-to-assets is 2.1%. Total assets: $4M.

Analyst outlook: 5 / 5 analysts rate BPTH as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

BPTH SharesGrow Score Overview

48/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BPTH

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
BPTH: +0%/yr revenue is, -3.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet BPTH: Debt-to-Equity (D/E) ratio 0.54 (moderate), Current ratio is 1.15 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
BPTH: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 5 / 5 analysts rate BPTH as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.05-0.23
Volume176
Avg Volume (30D)11.67K
Market Cap$582.95K
Beta (1Y)-0.33
Share Statistics
EPS (TTM)-4.12
Shares Outstanding$2.4M
IPO Date2008-03-04
Employees10
CEOVikram Paul Grover
Financial Highlights & Ratios
Net Income$-9.89M
Total Cash$1.17M
Total Debt$83K
Net Debt$-1.09M
Total Assets$3.88M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusBuy
Analysts Covering5
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS09057N4097

Price Chart

Track all markets on TradingView
BPTH
Bio-Path Holdings, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.05 52WK RANGE 0.23

People Also View

CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 CAPR
CAPR
Capricor Therapeutics, Inc.
$34.72
+0.52%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 BNTC
BNTC
Benitec Biopharma Inc.
$13.25
+10.42%
 ACHV
ACHV
Achieve Life Sciences, Inc.
$3.61
+0.84%
 ALRN
ALRN
Aileron Therapeutics, Inc.
$2.11
+9.33%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message